Submit Your Article CMED MEACR meeting
Home Print this page Email this page Users Online: 600
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Year : 2013  |  Volume : 2  |  Issue : 3  |  Page : 195-201

Targeted therapy for metastatic renal cell carcinoma: Current treatment and future directions

1 Department of Medical Oncology, National Institute of Oncology, Rabat, Morocco
2 Department of Medical Oncology, University Hospital of Mohammed VI, Marrakech, Morocco

Correspondence Address:
Noura Majid
Department of Medical Oncology, National Institute of Oncology, Boulevard Allal El Fassi 10100 Rabat
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/2278-0513.119257

Rights and Permissions

Renal cell carcinoma (RCC) is the most common renal tumor and accounts for 3% of all adult cancers. The treatment of metastatic renal cell carcinoma (mRCC) has recently evolved from being a predominantly cytokine-based treatment to the use of targeted agents, which include Sorafenib, Sunitinib, Bevacizumab, Temsirolimus, Everolimus, Pazopanib, Axitinib, and most recently Tivozanib. Despite these advances mRCC remains a major health problem. Additional studies are needed to optimize the use of these agents in both advanced and early stage disease, either in combination or sequentially. In addition the development of biomarkers should be a priority in order to guide rational tailored development of emerging agents. This literature review was conducted using PubMed, Medline, and Cochrane databases for articles published until January 2013. Abstracts from relevant meeting of the American Society of Clinical Oncology and the European society of medical oncology were also included.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded153    
    Comments [Add]    

Recommend this journal